Form 6K BioLineRx Ltd. For: 24 November
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioLineRx Ltd (BLRX)
Assess today's live BioLineRx Ltd (BLRX) share price, performance and insights using our live NASDAQ: BLRX stock exchange data.
Analyse the historical data and BioLineRx Ltd share price performance charts on this page. Our technical summary section provides analysis on BioLineRx share price buy/sell indicators using real-time data (or discuss the BioLineRx (BLRX) stock price today with other investors in the BioLineRx NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BLRX share price (ISIN: US09071M3043) to enhance your trading decisions with our free investment tools and resources.
What Is the BioLineRx Ltd Share Price Today?
The BioLineRx share price today is 3.000.
What Is the Stock Symbol for BioLineRx Ltd
The stock symbol (or 'ticker') for BioLineRx Ltd is "BLRX."
What Stock Exchange Does BioLineRx Ltd Trade On?
BioLineRx Ltd is listed and trades on the NASDAQ stock exchange.
Is BioLineRx Ltd a Good Stock to Buy?
Determining whether BioLineRx Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and BioLineRx Ltd share price performance charts on this page. Our technical summary section provides analysis on BioLineRx share price buy/sell indicators using real-time data (or discuss the BioLineRx (BLRX) stock price today with other investors in the BioLineRx NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BLRX share price (ISIN: US09071M3043) to enhance your trading decisions with our free investment tools and resources.
What Is the BioLineRx Ltd Share Price Today?
The BioLineRx share price today is 3.000.
What Is the Stock Symbol for BioLineRx Ltd
The stock symbol (or 'ticker') for BioLineRx Ltd is "BLRX."
What Stock Exchange Does BioLineRx Ltd Trade On?
BioLineRx Ltd is listed and trades on the NASDAQ stock exchange.
Is BioLineRx Ltd a Good Stock to Buy?
Determining whether BioLineRx Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.850
3.000
52 wk Range
2.300
14.696
BLRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8503.000
52 wk Range
2.30014.696
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
20.333
Upside
+577.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
BioLineRx Company Profile
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd Earnings Call Summary for Q3/2025
- BioLineRx reported Q3 2025 revenue of $0.4M, missing forecasts by 90.69%, with shares falling 3.85% to $3.25 following the announcement
- Despite revenue shortfall, net loss narrowed to $1M from $5.8M in Q3 2024, with R&D expenses reduced to $1.7M from $2.6M year-over-year
- Cash position of $25.2M is sufficient to fund operations into H1 2027, providing runway for planned clinical developments
- Company plans to initiate Phase 1/2a trial for GlyxOne in glioblastoma in Q1 2026, with Phase 1 data expected in H1 2027
- CEO Phil Serlin highlighted GlyxOne's market potential, stating 'We view this as a wide-open market with few competitors'
Last Updated: 24/11/2025, 14:18
Read Full TranscriptCompare BLRX to Peers and Sector
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.4x | −4.2x | −0.6x | |
PEG Ratio | −0.05 | −0.01 | 0.00 | |
Price/Book | 0.7x | 2.2x | 2.6x | |
Price / LTM Sales | 1.0x | 20.7x | 3.2x | |
Upside (Analyst Target) | - | 164.9% | 41.8% | |
Fair Value Upside | Unlock | 3.4% | 5.1% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.333
(+577.78% Upside)
Earnings
Latest Release
Nov 24, 2025
EPS / Forecast
-- / -0.08
Revenue / Forecast
430.00K / 4.62M
People Also Watch
FAQ
What Is the BioLineRx (BLRX) Share Price Today?
The live BioLineRx share price today is 3.000
What Stock Exchange Does BioLineRx (BLRX) Trade On?
BioLineRx is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for BioLineRx?
The stock symbol (also called a 'ticker') for BioLineRx is "BLRX."
What Is the Current BioLineRx Market Cap?
As of today, BioLineRx market capitalisation is 13.13M.
What Is BioLineRx's (BLRX) Earnings Per Share (TTM)?
The BioLineRx EPS is currently -0.00 (Trailing Twelve Months).
When Is the Next BioLineRx Earnings Date?
BioLineRx's next earnings report will be released on 24 Nov 2025.
Is BLRX a Buy or Sell From a Technical Analyst Perspective?
Based on today's BioLineRx moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BioLineRx Stock Split?
BioLineRx has split 2 times. (See the BLRX stock split history page for full effective split date and price information.)
How Many Employees Does BioLineRx Have?
BioLineRx has 28 employees.
What is the current trading status of BioLineRx (BLRX)?
As of 24 Dec 2025, BioLineRx (BLRX) is trading at a price of 3.000, with a previous close of 2.880. The stock has fluctuated within a day range of 2.850 to 3.000, while its 52-week range spans from 2.300 to 14.696.
What Is BioLineRx (BLRX) Price Target According to Analysts?
The average 12-month price target for BioLineRx is USD20.33333, with a high estimate of USD26 and a low estimate of USD12. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +577.78% Upside potential.
What Is the BLRX Premarket Price?
BLRX's last pre-market stock price is 2.980. The pre-market share volume is 250.000, and the stock has decreased by 0.100, or 3.470%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.